Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Xenon Pharmaceuticals Inc (NQ: XENE )

42.49 +1.84 (+4.53%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Xenon Pharmaceuticals Inc

< Previous 1 2 3 4 Next >
Boeing To Rally More Than 25%? Here Are 10 Top Analyst Forecasts For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
Xenon Pharma's Depression Candidate Shows Positive Signals Of Efficacy, Despite Primary Endpoint Miss: Analyst
Monday, Xenon Pharmaceuticals Inc (NASDAQ: XENE) reported topline results from the Phase 2 proof-of-concept X-NOVA trial, which evaluated the clinical efficacy, safety, and tolerability of 10 mg and 20... 
Via Benzinga
Why Anavex Life Sciences Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Anavex Life Sciences Corp. (NASDAQ: AVXL) moved lower during Monday’s session after the company reported fourth-quarter financial results. 
Via Benzinga
Xenon Pharmaceuticals: Q3 Earnings Insights
Via Benzinga
Earnings Outlook For Xenon Pharmaceuticals
Via Benzinga
Expert Ratings for Xenon Pharmaceuticals
Via Benzinga
Analyst Ratings for Xenon Pharmaceuticals
Via Benzinga
Earnings Scheduled For February 29, 2024
Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million. 
Via Benzinga
Earnings Outlook For Xenon Pharmaceuticals
Via Benzinga
3 Biotech Stocks That Could Be Multibaggers in the Making: February Edition
Now could be the time to start looking into these biotech stocks as there are imminent approvals on their clinical trials. 
Via InvestorPlace
This Analyst Is Bullish On Biohaven's Approach in Neuro-Psych Space
Biohaven's potential with RBC Capital Markets' optimistic outlook.. RBC sees blockbuster potential of $3.2 billion across epilepsy and mood disorders. Anticipate significant developments in lead asset... 
Via Benzinga
4 Analysts Have This to Say About Xenon Pharmaceuticals
Via Benzinga
Why Xenon Pharmaceuticals Stock (XENE) Is Seeing Blue Skies Today
Xenon Pharmaceuticals Inc (NASDAQ: XENE) shares are trading higher by 7.8% to $36.38 Thursday afternoon. The company announced the pricing of its upsized $300 million public offering of 8,461,542... 
Via Benzinga
Xenon Pharmaceuticals: Q1 Earnings Insights
Via Benzinga
Where Xenon Pharmaceuticals Stands With Analysts
Via Benzinga
Earnings Scheduled For March 1, 2023
Companies Reporting Before The Bell • Globalstar (AMEX:GSAT) is expected to report quarterly loss at $0.01 per share on revenue of $38.75 million. 
Via Benzinga
Xenon Pharmaceuticals Earnings Preview
Via Benzinga
The Latest Analyst Ratings for Xenon Pharmaceuticals
Via Benzinga
The Unexpected Depression Drug News That Sent Xenon Pharmaceuticals Soaring
The company's epilepsy drug also showed promise as a depression treatment. 
Via Investor's Business Daily
What's Going On With Neurology-Focused Xenon Pharmaceuticals' Stock Today?
Xenon Pharmaceuticals Inc (NASDAQ: XENE) reported topline results from the Phase 2 proof-of-concept X-NOVA trial, which evaluated the clinical efficacy, safety, and tolerability of 10 mg and 20 mg of... 
Via Benzinga
Ituran Location and Control Posts Q3 Results, Joins Crown Castle, Shopify And Other Big Stocks Moving Higher On Monday
U.S. stocks traded mostly lower, with the Dow Jones falling around 50 points on Monday. Shares of Ituran Location and Control Ltd. (NASDAQ: ITRN) gained during Monday’s session after the company... 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Is Neurocrine Biosciences Stock Trading Lower Today?
Thursday, Neurocrine Biosciences Inc (NASDAQ: NBIX)  
Via Benzinga
Unlocking Xenon Pharmaceuticals $1B Potential: Analyst Cites Anti-Epileptic Candidate's Untapped Value
Cantor Fitzgerald has initiated coverage on Xenon Pharmaceuticals Inc (NASDAQ: XENE) with an Overweight rating and a  
Via Benzinga
Analyst Ratings for Xenon Pharmaceuticals
Via Benzinga
Earnings Scheduled For November 8, 2023
Companies Reporting Before The Bell • Flex LNG (NYSE:FLNG) is estimated to report earnings for its third quarter. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 25, 2023
Via Benzinga
Earnings Scheduled For May 9, 2023
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.17 per share on revenue of $440.16 million. 
Via Benzinga
Benzinga Pro's Top 5 Stocks To Watch For Tuesday, April 25, 2023: GM, SNAP, WEN, XENE, CXAI
General Motors (GM) - Shares traded about 3% higher Tuesday morning following better-than-expected Q1 earnings and sales and raised guidance. The company said global deliveries of its automobiles 
Via Benzinga
Here's What's Next For Biohaven After Its $12 Billion Pfizer Buyout, According To CEO Vlad Coric
The company that remains still has a large pipeline of non-migraine assets. 
Via Investor's Business Daily
Applied UV (NASDAQ: AUVI) Effectively Doubles Its Size Following A Merger That Could Help Shape The Industry – A Brief Look At The Company
A recent merger between Applied UV Inc. (NASDAQ: AUVI), Puro Lighting (PURO), and LED Supply Co. (LED Supply) seems to have triggered some excitement in the ultraviolet (UV) disinfection equipment... 
Via Benzinga
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.